Session 3 – Advances in Precision Medicine
Date: 25 July (Thursday) 09:00 – 12:00 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
JARRET C.J. SU (Chia-Jui, SU)
Co-Head of Healthcare and Life Science
Jarret is Co-Head of Healthcare & Life Science at KPMG Advisory Services Co., Ltd. and senior lawyer at KPMG Law Firm. He has over 20 years of clinical experience in medical practice, and also practiced law as a qualified attorney in Taiwan and in the USA. He had served as a member of IRB, School of Medicine, Washington University in St. Louis, USA, and now serves as a member of the Advisory Committee of Regeneration medicine, TFDA. Jarret provides advisory services to deal with the healthcare and bio-pharmaceutics issues, such as clinical trial, licensing, drug pricing, reimbursement, merge & acquisition, and IPO. Jarret are also in charge of the governmental projects focusing on regulation framework including Precision medicine, Cell therapies, and many healthcare related issues. The abundant experiences and great enthusiasm that Jarret possesses in the life science and healthcare profession has empowered him to be the pioneer and an expert in the relevant businesses. Session Speech Title & Synopsis: Clinical Applications and Regulatory Frameworks in Precision Medicine -- From Taiwan to Asia
The clinical application and regulatory compliance are truly important for industrial stakeholders working on precision medicine and advanced treatments. First, we will look into the present and future development of industrial ecosystem on precision medicine, which includes cell therapy, immune therapy, molecular diagnostics, etc. Then we will elaborate on regulatory framework, including the different trends in Japan, USA, EU, and Taiwan, and how this should be the optimal way to accelerating advanced treatment from clinical trials to regular practices and to collaborating medical researches with biotech industries. Meanwhile, it’s worth mentioning that Taiwan also just implements a novel regular framework on cell therapies and LDTs. Finally, we will conclude by how to integrate and synergize these regulatory impacts and industrial developments in precision medicine.